Salubris disclosed on May 17, 2024 in the Shenzhen Stock Exchange that as of April 19, 2024, the number of shareholders of the company was 27,700, a decrease of 607 or 2.15% from the previous period (March 31, 2024).
The number of Salubris shareholders is lower than the industry average. According to Choice data, as of April 19, 2024, the average number of shareholders of listed companies in the pharmaceutical and biotechnology industry is 33,900. Among them, the number of shareholders of the company is in the range of 5,000~15,000, accounting for the highest proportion, 29.05%.
Distribution of the number of shareholders in the pharmaceutical and biological industry
Number of shareholders and share price
Since February 8, 2024, the number of shareholders of the company has increased, with an increase of 1.69%. From February 8, 2024 to April 19, 2024, the stock price decreased by 9.08%.
Number of shareholders and share price
Number of shareholders and share capital
As of April 19, 2024, the company's latest outstanding share capital is 1.115 billion shares. The average number of outstanding shares held by households increased from 39,400 shares in the previous period to 40,300 shares, and the average market value of households was 1,132,800 yuan.
The average amount of shares held by each household
Salubris accounts hold a circulating market value higher than the industry average. According to Choice data, as of April 19, 2024, the average market value of A-share listed companies in the pharmaceutical and biological industry is 402,200 yuan. Among them, 25.31% of the company's households hold a circulating stock market value in the range of 130,000~250,000.
Distribution of per capita circulating market value of the pharmaceutical and biological industry
SZSE shareholdings
On April 19, 2024, the number of shares held by Shenzhen Stock Connect was 15,732,200 shares, accounting for 1.41% of the outstanding share capital, an increase of 5.62% from 14,895,800 shares in the previous period (March 31, 2024).
SZSE shareholding chart
Disclaimer: This article is based on big data and is for reference only and does not constitute any investment advice.